While the examination of the PLFSS 2025 is underway in Parliament, and the Leem (French Pharmaceutical Professional Organization) has just signed an unprecedent agreement with the government, we offer you this new position paper, which provides key insights on the regulation of healthcare costs in France.
This document highlights:
- Key macroeconomic indicators (2019-2024)
- National Health Insurance Fund deficit (2009-2024)
- Government’s levers to regulate drug public spending
- Drugs price international comparisons (2023)
- Drugs rebates to the National Health Insurance Fund (2022)
- Safeguard clause clawback definition, principles and calculation (2019-2023)
- Key regulatory changes expected (2024-2028)